Skip to content

A Comparison of Two Color Contact Lenses in Habitual Clear Contact Lens Wearers

A Comparison of Two Color Contact Lenses in Habitual Clear Contact Lens Wearers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02175199
Enrollment
151
Registered
2014-06-26
Start date
2014-06-30
Completion date
2014-09-30
Last updated
2015-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Keywords

Contact lens, Vision care, Daily wear, Color contact lens

Brief summary

The purpose of this study is to evaluate the comfort of color contact lenses in a population of clear contact lens wearers who have an interest in wearing color contact lenses.

Interventions

DEVICELotrafilcon B contact lenses with color printing
DEVICEPhemfilcon A contact lenses with color printing

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Willing to sign an Informed Consent Document or Assent, if applicable. * Vision correctable to 20/30 Snellen (feet) or better in each eye at distance with pre-study contact lenses. * Manifest cylinder (at screening) less than or equal to 0.75 diopters (D) in each eye. * Successful wear of clear/handling tint, single-vision spherical, bi-weekly/ monthly replacement soft contact lenses in both eyes during the past 2 months for a minimum of 5 days per week and 8 hours per day. * Requires spherical contact lenses within the available range of powers (i.e.,-1.50D to -5.00D in 0.25D steps). * Interested in wearing contact lenses that change the appearance of the color of the eyes. * Other protocol-specified inclusion criteria may apply.

Exclusion criteria

* Any anterior segment infection, inflammation, disease or abnormality that contraindicates contact lens wear (within 7 days of enrollment, or current). * History of herpetic keratitis. * Any use of systemic or ocular medications for which contact lens wear could be contraindicated including any use of topical ocular medications that would require instillation during contact lens wear, except for rewetting drops. * Corneal vascularization greater than 1 millimeter (mm) of penetration. * Habitual lenses worn in an extended wear modality (routinely sleeping in lenses overnight for 1 night per week or more) over the last 3 months prior to enrollment. * Previous corneal or refractive surgery or irregular cornea. * Monovision and monocular (only 1 eye with functional vision) or fit with only 1 lens. * Anisometropia ≥1.50D (study contact lens prescription). * History of intolerance or hypersensitivity to any component of the test articles. * Eye injury or ocular or intra-ocular surgery within the last 6 months (excluding placement of punctal plugs). * Participation in any clinical study within 30 days of Visit 1. * Other protocol-specified

Design outcomes

Primary

MeasureTime frameDescription
Lens Comfort Likert Response at Day 30Day 30Subject indicated agreement with the following statement, These lenses provided the same excellent comfort at the end of the month as they did at the beginning of the month using a 4-point Likert scale, where 1=Strongly disagree, 2=Disagree; 3=Agree; 4=Strongly agree. The Top 2 responses (agree, strongly agree) were calculated and reported as a percentage of all responses. Both eyes were rated together. This outcome measure was prespecified for the AIR OPTIX COLORS arm only.

Secondary

MeasureTime frameDescription
Lens Comfort Likert Response at Day 14Day 14Subject indicated agreement with the following statement, These lenses provided the same excellent comfort at the end of two weeks as they did at the beginning of the two weeks using a 4-point Likert scale, where 1=Strongly disagree, 2=Disagree; 3=Agree; 4=Strongly agree. The Top 2 responses (agree, strongly agree) were calculated and reported as a percentage of all responses. Both eyes were rated together. This outcome measure is prespecified for the AIR OPTIX COLORS arm only.
Lens Comfort 1-10 Scale ResponseDay 30Subject was instructed, Please rate your comfort with the study lenses, using a scale from 1-10, where 1=poor and 10=excellent. Both eyes were rated together.

Participant flow

Recruitment details

Subjects were recruited from 10 Study Centers located in the US.

Pre-assignment details

Of the 151 enrolled, 1 subject was exited as a screen failure prior to randomization. This reporting group includes all randomized subjects (150).

Participants by arm

ArmCount
AIR OPTIX COLORS
Contact lenses with color printing worn bilaterally in a daily wear modality 5 days/week, 8 hours/day for 30 days.
72
FreshLook COLORBLENDS
Contact lenses with color printing worn bilaterally in a daily wear modality 5 days/week, 8 hours/day for 30 days with a 2-week replacement.
74
Total146

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyRandomized in Error10
Overall StudySponsor Decision10
Overall StudyWithdrawal by Subject15

Baseline characteristics

CharacteristicAIR OPTIX COLORSFreshLook COLORBLENDSTotal
Age, Continuous29.9 years
STANDARD_DEVIATION 7.91
29.4 years
STANDARD_DEVIATION 7.62
29.7 years
STANDARD_DEVIATION 7.74
Sex: Female, Male
Female
67 Participants60 Participants127 Participants
Sex: Female, Male
Male
5 Participants14 Participants19 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
0 / 1510 / 1440 / 148
serious
Total, serious adverse events
0 / 1510 / 1440 / 148

Outcome results

Primary

Lens Comfort Likert Response at Day 30

Subject indicated agreement with the following statement, These lenses provided the same excellent comfort at the end of the month as they did at the beginning of the month using a 4-point Likert scale, where 1=Strongly disagree, 2=Disagree; 3=Agree; 4=Strongly agree. The Top 2 responses (agree, strongly agree) were calculated and reported as a percentage of all responses. Both eyes were rated together. This outcome measure was prespecified for the AIR OPTIX COLORS arm only.

Time frame: Day 30

Population: This analysis population includes all randomized subjects excluding those who met the critical deviation criteria as specified in the Deviations and Evaluability Plan (DEP).

ArmMeasureValue (NUMBER)
AIR OPTIX COLORSLens Comfort Likert Response at Day 3081.4 percentage of subjects
Secondary

Lens Comfort 1-10 Scale Response

Subject was instructed, Please rate your comfort with the study lenses, using a scale from 1-10, where 1=poor and 10=excellent. Both eyes were rated together.

Time frame: Day 30

Population: This analysis population includes all randomized subjects with data at visit excluding those who met the critical deviation criteria as specified in the Deviations and Evaluability Plan (DEP).

ArmMeasureValue (MEAN)Dispersion
AIR OPTIX COLORSLens Comfort 1-10 Scale Response8.0 units on a scaleStandard Deviation 1.99
FreshLook COLORBLENDSLens Comfort 1-10 Scale Response7.3 units on a scaleStandard Deviation 2.19
Secondary

Lens Comfort Likert Response at Day 14

Subject indicated agreement with the following statement, These lenses provided the same excellent comfort at the end of two weeks as they did at the beginning of the two weeks using a 4-point Likert scale, where 1=Strongly disagree, 2=Disagree; 3=Agree; 4=Strongly agree. The Top 2 responses (agree, strongly agree) were calculated and reported as a percentage of all responses. Both eyes were rated together. This outcome measure is prespecified for the AIR OPTIX COLORS arm only.

Time frame: Day 14

Population: This analysis population includes all randomized subjects with data at visit excluding those who met the critical deviation criteria as specified in the Deviations and Evaluability Plan (DEP).

ArmMeasureValue (NUMBER)
AIR OPTIX COLORSLens Comfort Likert Response at Day 1489.9 percentage of subjects

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026